On Feb. 13, 2020, scientists at HDT Bio announced development of a vaccine to protect against the 2019-novel coronavirus (COVID-19) based upon RNA-based technology, a specialty of the company.

The HDT Bio-led consortium included vaccine experts from Seattle-based PAI Life Sciences, the University of Washington (UW) School of Medicine and InBios International, a Seattle-based infectious disease diagnostics company.